Skip to content

Postpartum depression: A role for psychedelics?

Chaitra Jairaj, James J Rucker

Journal of Psychopharmacology May 30, 2022 DOI: 10.1177/02698811221093793 via OpenAlex

Summary

AI-generated from the abstract

Postpartum depression (PPD) involves a core sense of maternal disconnection from self, infant, and support system, and differs from major depressive disorder (MDD), especially regarding the mother-infant relationship. Current PPD treatments, borrowed from MDD, show low remission rates and emerging treatment resistance. This narrative review proposes that serotonergic psychedelics, particularly psilocybin, could treat PPD by fostering reconnection. Evidence from MDD trials indicates psilocybin is safe and shows encouraging efficacy, catalyzing reconnection. In PPD, this reconnection might improve mood and maternal sensitivity, enhancing maternal role gratification and the mother-infant relationship. Psychedelic-assisted therapy for PPD warrants further examination.

Study at a glance

Characteristics Narrative review Peer reviewed
Interventions Serotonergic psychedelics Psilocybin
Topics Depression Psilocybin
Keywords Postpartum depression Mood Disconnection
Citations 13
Key finding Serotonergic psychedelics, especially psilocybin, may treat postpartum depression by fostering maternal reconnection, improving mood and the mother-infant relationship.

Abstract

Background: Postpartum depression (PPD) is a major public health concern and has, at its core, a sense of maternal ‘disconnection’ – from the self, the infant, and the support system. While PPD bears similarities with MDD, there is increasing evidence for its distinct nature, especially with the unique aspect of the mother-infant relationship. Current treatment modalities for PPD, largely based on those used in major depressive disorder (MDD), have low remission rates with emerging evidence for treatment resistance. It is, therefore, necessary to explore alternative avenues of treatment for PPD. Objective: In this narrative review, we outline the potential therapeutic rationale for serotonergic psychedelics in the treatment of PPD, and highlight safety and pragmatic considerations for the use of psychedelics in the postpartum period. Methods: We examined the available evidence for the treatment of PPD and the evidence for psychedelics in the treatment of MDD. We explored safety considerations in the use of psychedelics in the postpartum period. Results: There is increasing evidence for safety, and encouraging signals for efficacy, of psilocybin in the treatment of MDD. Psilocybin has been shown to catalyse a sense of ‘reconnection’ in participants with MDD. This effect in PPD, by fostering a sense of ‘reconnection’ for the mother, may allow for improved mood and maternal sensitivity towards the infant, which can positively impact maternal role gratification and the mother-infant relationship. Conclusion: Psychedelic assisted therapy in PPD may have a positive effect on the mother-infant dyad and warrants further examination.

Explore topics

Comments

No comments yet.

Log in to comment